- Home
- LNT vs BBIO Comparison
LNT vs BBIO Comparison
Compare LNT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNT | BBIO |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 15.9B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LNT | BBIO |
|---|---|---|
| Price | $70.21 | $84.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 25 |
| Target Price | $74.56 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 2.6M | 2.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | ★ 16.73 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $4,362,000,000.00 | $502,076,000.00 |
| Revenue This Year | $4.61 | $89.45 |
| Revenue Next Year | $6.33 | $73.78 |
| P/E Ratio | $80.44 | ★ N/A |
| Revenue Growth | 9.57 | ★ 126.26 |
| 52 Week Low | $63.28 | $46.81 |
| 52 Week High | $78.81 | $93.42 |
Technical Indicators
Market Signals| Indicator | LNT | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.